The United Kingdom and the United States have signed a significant bilateral deal that will preserve zero levies on UK pharmaceutical products entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial goods will stay at zero for a duration of 36 months.
This agreement follows previous threats to significantly raise tariffs on branded pharmaceutical products, with potential rates discussed as high as double the cost.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," an announcement noted.
Trade Impact
Medicines are one of the UK's most significant exports to the United States, which is easily the largest buyer for large British pharmaceutical firms.
Export figures indicate that in the year leading up to the third quarter, the UK sold drugs valued at £11.1bn to the US. This value represented 17.4% of total UK exports in that timeframe.
"This guarantee secures employment, boosts funding and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several key commitments from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates were more than 20%.
Recent Tensions
This agreement follows a ongoing row between the drug companies and the British authorities over medicine costs and approval rates.
The disagreement were intensified by claims that US consumers were charged significantly more for the same drugs than people in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a percentage of its overall budget over the previous ten-year period.
